What is the 13F Pro Quality Score for INDV?

13F Pro ranks Indivior Pharmaceuticals, Inc. (INDV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View INDV's current score at https://13fpro.ai/research/INDV (free sign-up required for the full ranking).

Where does 13F Pro source INDV data?

All Indivior Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Indivior Pharmaceuticals, Inc. files with the SEC under CIK 1625297. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is INDV in?

Indivior Pharmaceuticals, Inc. (INDV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is INDV research updated on 13F Pro?

INDV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Indivior Pharmaceuticals, Inc.(INDV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1625297 INDV stock profile & AI dashboard →

13F Pro Quality Score

64.6/100

Rank #627 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

47.0/100

Profitability

79.1/100

Balance Sheet

94.3/100

Earnings Quality

97.9/100

Free Cash Flow

64.0/100

Institutional Flow

16.4/100

Revenue Scale

52.8/100

Dilution Risk

40.6/100

INDV Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Indivior Pharmaceuticals, Inc. (INDV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INDV at 64.6/100 on a 32-signal composite quality model, placing it at rank #627 of 2,879 stocks — the top 25% of the AI-ranked universe. INDV scores in the top quartile across earnings quality (97.9), balance sheet strength (94.3), profitability (79.1). Areas of concern include institutional flow (16.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 40.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Indivior Pharmaceuticals, Inc. reports quarterly revenue of $317.0M, net income of $89.0M, free cash flow of $-29.0M. Top institutional holders of INDV by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. INDV trades on the Nasdaq exchange and files with the SEC under CIK 1625297. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INDV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Indivior Pharmaceuticals, Inc. directly from SEC EDGAR. Indivior Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 37 and 65 since 2026, currently 64.6 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about Indivior Pharmaceuticals, Inc.

Quirks, history, and lore behind INDV — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · listed on Nasdaq · headquartered in Virginia · focused entirely on addiction treatment.
2
The Numbers
Annual revenue in the range of roughly $1 billion, with a product portfolio that lives or dies on a single therapeutic category: opioid use disorder.
3
The History
The company was spun off from Reckitt Benckiser — yes, the cleaning-products giant — around 2014, taking its addiction medicine franchise with it as an independent entity.
4
The Secret
It has faced significant legal scrutiny over marketing practices, including a major U.S. Department of Justice settlement, making its history almost as troubled as the epidemic it treats.
5
The Lore
Its flagship treatment comes in a dissolvable film strip placed under the tongue — a delivery format so distinctive it helped define how doctors think about medication-assisted opioid treatment.
6
The Giveaway
The maker of Suboxone — the buprenorphine-naloxone film that became the standard of care for opioid dependence — and the company that fought (and lost) patent battles to keep generic rivals at bay.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$317.0M

Net Income

Q1 2026

$89.0M

Free Cash Flow

Q1 2026

$-29.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+4.3% YoY

$1.24BFY 2025

FY22 $901.0MFY23 $1.09BFY24 $1.19BFY25 $1.24B

Net Income

+2900.0% YoY

$210.0MFY 2025

FY22 $-42.0MFY23 $-126.0MFY24 $7.0MFY25 $210.0M

Operating Income

+589.5% YoY

$262.0MFY 2025

FY22 $-77.0MFY23 $-152.0MFY24 $38.0MFY25 $262.0M

EPS (Diluted)

+3180.0% YoY

$1.64FY 2025

FY22 $-0.32FY23 $-0.92FY24 $0.05FY25 $1.64

Total Assets

-8.7% YoY

$1.20BFY 2025

FY22 $1.77BFY23 $1.76BFY24 $1.32BFY25 $1.20B

Total Debt

-4.2% YoY

$319.0MFY 2025

FY22 —FY23 $240.0MFY24 $333.0MFY25 $319.0M

Op. Cash Flow

-175.0% YoY

$-27.0MFY 2025

FY22 $-4.0MFY23 $-300.0MFY24 $36.0MFY25 $-27.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$1.24B +4.3%	$1.19B +8.7%	$1.09B +21.3%	$901.0M	—
Net Income	$210.0M +2900.0%	$7.0M +105.6%	$-126.0M -200.0%	$-42.0M	—
Operating Income	$262.0M +589.5%	$38.0M +125.0%	$-152.0M -97.4%	$-77.0M	—
EPS (Diluted)	$1.64 +3180.0%	$0.05 +105.4%	$-0.92 -187.5%	$-0.32	—
Total Assets	$1.20B -8.7%	$1.32B -25.1%	$1.76B -0.6%	$1.77B -3.4%	$1.83B
Total Debt	$319.0M -4.2%	$333.0M +38.8%	$240.0M	—	—
Operating Cash Flow	$-27.0M -175.0%	$36.0M +112.0%	$-300.0M -7400.0%	$-4.0M	—

Get alerted when INDV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Indivior Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of INDV

BlackRock, Inc.
$565.2M18,542,220 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$240.5M7,891,819 sh
VANGUARD CAPITAL MANAGEMENT LLC
$170.3M5,586,576 sh
STATE STREET CORP
$149.5M4,903,993 sh
Two Seas Capital LP
$144.7M4,746,510 sh
MILLENNIUM MANAGEMENT LLC
$140.1M4,595,535 sh
FULLER & THALER ASSET MANAGEMENT, INC.
$138.1M4,529,583 sh
Madison Avenue Partners, LP
$131.5M4,315,162 sh
CITADEL ADVISORS LLC
$108.9M3,574,044 sh
MORGAN STANLEY
$106.9M3,505,817 sh

Fund	Value	Shares
BlackRock, Inc.	$565.2M	18,542,220
VANGUARD PORTFOLIO MANAGEMENT LLC	$240.5M	7,891,819
VANGUARD CAPITAL MANAGEMENT LLC	$170.3M	5,586,576
STATE STREET CORP	$149.5M	4,903,993
Two Seas Capital LP	$144.7M	4,746,510
MILLENNIUM MANAGEMENT LLC	$140.1M	4,595,535
FULLER & THALER ASSET MANAGEMENT, INC.	$138.1M	4,529,583
Madison Avenue Partners, LP	$131.5M	4,315,162
CITADEL ADVISORS LLC	$108.9M	3,574,044
MORGAN STANLEY	$106.9M	3,505,817

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put INDV on your watchlist

Track score changes the day Indivior Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is INDV a good stock to buy?

13F Pro's AI-powered analysis of Indivior Pharmaceuticals, Inc. (INDV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INDV are available on the INDV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own INDV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INDV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Indivior Pharmaceuticals, Inc.'s investment landscape.